Your browser doesn't support javascript.
loading
Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma.
Budde, Lihua E; Berger, Carolina; Lin, Yukang; Wang, Jinjuan; Lin, Xubin; Frayo, Shani E; Brouns, Shaunda A; Spencer, David M; Till, Brian G; Jensen, Michael C; Riddell, Stanley R; Press, Oliver W.
Affiliation
  • Budde LE; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, United States of America ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America ; Departments of Medicine and Bioengineering, University of
  • Berger C; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Lin Y; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Wang J; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Lin X; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Frayo SE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Brouns SA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Spencer DM; Pathology and Immunology, Baylor College of Medicine, Houston, Texas, United States of America ; Bellicum Pharmaceuticals, Inc., Houston, Texas, United States of America.
  • Till BG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America ; Departments of Medicine and Bioengineering, University of Washington, Seattle, Washington, United States of America.
  • Jensen MC; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America ; Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington, United States of America.
  • Riddell SR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America ; Departments of Medicine and Bioengineering, University of Washington, Seattle, Washington, United States of America ; Institute for Advanced Study, Technical University of Munich, Muni
  • Press OW; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America ; Departments of Medicine and Bioengineering, University of Washington, Seattle, Washington, United States of America.
PLoS One ; 8(12): e82742, 2013.
Article in En | MEDLINE | ID: mdl-24358223
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Antigen, T-Cell / T-Lymphocytes / Immunotherapy, Adoptive / Antigens, CD20 / Genes, Transgenic, Suicide / Caspase 9 / Lymphoma Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2013 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Antigen, T-Cell / T-Lymphocytes / Immunotherapy, Adoptive / Antigens, CD20 / Genes, Transgenic, Suicide / Caspase 9 / Lymphoma Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2013 Document type: Article Country of publication: United States